All In Biotech

Drug Trial Radar · NCT01633177

Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes

Diabetes Prevention in the Vitamin D and Omega-3 Trial

Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 22,220 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

22,220

Actual

Start

Nov 2011

Primary completion

May 30, 2024

Study completion May 30, 2024

Sponsor

Lead sponsor
Brigham and Women's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted
Jul 4, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial in 25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among nondiabetic participants in VITAL and will examine whether vitamin D or fish oil prevent type 2 diabetes. Findings from this ancillary study (n=22220 without diabetes at baseline) conducted within the VITAL trial will clarify whether vitamin D and omega-3 fatty acid supplementation reduces risk of type 2 diabetes and thus will inform public health and clinical guidelines for diabetes prevention.

Conditions

  • Type 2 Diabetes

Interventions

  • Vitamin D3Dietary supplement

    Vitamin D3 (cholecalciferol), 2000 IU per day.

  • Omega-3 fatty acid (fish oil)Drug

    Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

  • Vitamin D3 placeboDietary supplement

    Vitamin D3 placebo

  • Fish oil placeboDrug

    Fish oil placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incident Type 2 DiabetesTime frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Division of Preventive Medicine, Brigham and Women's Hospital

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.